131 related articles for article (PubMed ID: 38773427)
1. Effect of novel anti-tumor and anti-angiogenesis drug taurolactone on angiogenic factor AGGF1 and angiogenesis mimicry in patients with hepatocellular carcinoma.
Liu S; Wei Y; Nie L; Tang Z; Lu Q; Liang Q
BMC Cancer; 2024 May; 24(1):614. PubMed ID: 38773427
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of AGGF1 is correlated with angiogenesis and poor prognosis of hepatocellular carcinoma.
Wang W; Li GY; Zhu JY; Huang DB; Zhou HC; Zhong W; Ji CS
Med Oncol; 2015 Apr; 32(4):131. PubMed ID: 25796501
[TBL] [Abstract][Full Text] [Related]
3. LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway.
Li W; Fu Q; Man W; Guo H; Yang P
Eur J Pharmacol; 2019 Apr; 849():106-114. PubMed ID: 30710550
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1) Acts as Diagnostic Biomarker and Adverse Prognostic Factor of Hepatocellular Carcinoma (HCC): Evidence from Bioinformatic Analysis.
Wang W; Zhu G; Lai S; Guo Y; Yin X; Chen D; Wen L
Med Sci Monit; 2020 Feb; 26():e919896. PubMed ID: 32090983
[TBL] [Abstract][Full Text] [Related]
5. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.
Wada H; Nagano H; Yamamoto H; Yang Y; Kondo M; Ota H; Nakamura M; Yoshioka S; Kato H; Damdinsuren B; Tang D; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Sakon M; Dono K; Wakasa K; Monden M
Liver Int; 2006 May; 26(4):414-23. PubMed ID: 16629644
[TBL] [Abstract][Full Text] [Related]
6. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
Hu C; Li W; Tian F; Jiang K; Liu X; Cen J; He Q; Qiu Z; Kienast Y; Wang Z; Zhang H; Ji Y; Hu J; Hui L
J Hepatol; 2018 Mar; 68(3):465-475. PubMed ID: 29113912
[TBL] [Abstract][Full Text] [Related]
7. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
Zheng N; Zhang S; Wu W; Zhang N; Wang J
Pharmacol Res; 2021 Apr; 166():105507. PubMed ID: 33610718
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
[TBL] [Abstract][Full Text] [Related]
9. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Kuczynski EA; Yin M; Bar-Zion A; Lee CR; Butz H; Man S; Daley F; Vermeulen PB; Yousef GM; Foster FS; Reynolds AR; Kerbel RS
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27059374
[TBL] [Abstract][Full Text] [Related]
10. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Nasr M; Selima E; Hamed O; Kazem A
Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
[TBL] [Abstract][Full Text] [Related]
11. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
12. High expression of angiogenic factor AGGF1 is an independent prognostic factor for hepatocellular carcinoma.
Tu J; Ying X; Zhang D; Weng Q; Mao W; Chen L; Wu X; Tu C; Ji J; Huang Y
Oncotarget; 2017 Dec; 8(67):111623-111630. PubMed ID: 29340079
[TBL] [Abstract][Full Text] [Related]
13. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
14. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
[TBL] [Abstract][Full Text] [Related]
15. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.
Wei Y; Yang Q; Zhang Y; Zhao T; Liu X; Zhong J; Ma J; Chen Y; Zhao C; Li J
Oncotarget; 2017 Feb; 8(9):15230-15241. PubMed ID: 28122355
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.
Carpizo DR; Gensure RH; Yu X; Gendel VM; Greene SJ; Moore DF; Jabbour SK; Nosher JL
J Vasc Interv Radiol; 2014 Feb; 25(2):297-306.e1. PubMed ID: 24360887
[TBL] [Abstract][Full Text] [Related]
17. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
Zhao ZC; Zheng SS; Wan YL; Jia CK; Xie HY
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):529-36. PubMed ID: 14627514
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N
Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?
Moon WS; Rhyu KH; Kang MJ; Lee DG; Yu HC; Yeum JH; Koh GY; Tarnawski AS
Mod Pathol; 2003 Jun; 16(6):552-7. PubMed ID: 12808060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]